

Marie-Christine Alessi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9061319/publications.pdf>

Version: 2024-02-01

329
papers

24,579
citations

6613

79
h-index

8167

148
g-index

352
all docs

352
docs citations

352
times ranked

24282
citing authors

#	ARTICLE	IF	CITATIONS
1	Atypical late diagnosis of Noonan syndrome revealed by bleedings due to platelet dysfunction. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 53, 557-560.	2.1	0
2	Platelets Purification Is a Crucial Step for Transcriptomic Analysis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3100.	4.1	7
3	On-Ticagrelor Platelet Reactivity and Clinical Outcome in Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndrome. <i>Thrombosis and Haemostasis</i> , 2021, 121, 923-930.	3.4	3
4	A rare coding mutation in the MAST2 gene causes venous thrombosis in a French family with unexplained thrombophilia: The Breizh MAST2 Arg89Gln variant. <i>PLoS Genetics</i> , 2021, 17, e1009284.	3.5	2
5	Severe thrombophilia in a factor Vâ€deficient patient homozygous for the Ala2086Asp mutation (FV) Tj ETQq1 1 0,784314 rgBT /Ov	3.8	15
6	The ISTH bleeding assessment tool as predictor of bleeding events in inherited platelet disorders: Communication from the ISTH SSC Subcommittee on Platelet Physiology. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1364-1371.	3.8	19
7	Impaired adhesion of neutrophils expressing Slc44a2/HNA-3b to VWF protects against NETosis under venous shear rates. <i>Blood</i> , 2021, 137, 2256-2266.	1.4	16
8	GATA1 pathogenic variants disrupt MYH10 silencing during megakaryopoiesis. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2287-2301.	3.8	6
9	Platelets: a potential role in chronic respiratory diseases?. <i>European Respiratory Review</i> , 2021, 30, 210062.	7.1	8
10	High prevalence of mutations in perilipin 1 in patients with precocious acute coronary syndrome. <i>Atherosclerosis</i> , 2020, 293, 86-91.	0.8	2
11	Validation of the ISTH/SSC bleeding assessment tool for inherited platelet disorders: A communication from the Platelet Physiology SSC. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 732-739.	3.8	64
12	Epinephrine restores platelet functions inhibited by ticagrelor: A mechanistic approach. <i>European Journal of Pharmacology</i> , 2020, 866, 172798.	3.5	10
13	A Combination of Single Nucleotide Polymorphisms is Associated with the Interindividual Variability of Cholesterol Bioavailability in Healthy Adult Males. <i>Molecular Nutrition and Food Research</i> , 2020, 64, 2000480.	3.3	3
14	Novel manifestations of immune dysregulation and granule defects in gray platelet syndrome. <i>Blood</i> , 2020, 136, 1956-1967.	1.4	34
15	Laboratory Techniques Used to Diagnose Constitutional Platelet Dysfunction. <i>Hamostaseologie</i> , 2020, 40, 444-459.	1.9	6
16	Strengths and Weaknesses of Light Transmission Aggregometry in Diagnosing Hereditary Platelet Function Disorders. <i>Journal of Clinical Medicine</i> , 2020, 9, 763.	2.4	20
17	Contribution of exome sequencing to the identification of genes involved in the response to clopidogrel in cardiovascular patients. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1425-1434.	3.8	2
18	Bernardâ€™Soulie syndrome: first human case due to a homozygous deletion of GP9 gene. <i>British Journal of Haematology</i> , 2020, 188, e87-e90.	2.5	1

#	ARTICLE	IF	CITATIONS
19	RasGRP2 Structure, Function and Genetic Variants in Platelet Pathophysiology. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1075.	4.1	20
20	An integrated approach to inherited platelet disorders: results from a research collaborative, the Sydney Platelet Group. <i>Pathology</i> , 2020, 52, 243-255.	0.6	15
21	Perioperative Open-lung Approach, Regional Ventilation, and Lung Injury in Cardiac Surgery. <i>Anesthesiology</i> , 2020, 133, 1029-1045.	2.5	23
22	A Novel Rapid Method of Red Blood Cell and Platelet Permeabilization and Staining for Flow Cytometry Analysis. <i>Cytometry Part B - Clinical Cytometry</i> , 2019, 96, 426-435.	1.5	5
23	Platelet reactivity inhibition following ticagrelor loading dose in patients undergoing percutaneous coronary intervention for acute coronary syndrome. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 2188-2195.	3.8	5
24	Novel <i>ACTN1</i> variants in cases of thrombocytopenia. <i>Human Mutation</i> , 2019, 40, 2258-2269.	2.5	5
25	Increased levels of the megakaryocyte and platelet expressed cysteine proteases stefin A and cystatin A prevent thrombosis. <i>Scientific Reports</i> , 2019, 9, 9631.	3.3	11
26	Platelet CD 40 ligand and bleeding during P2Y12 inhibitor treatment in acute coronary syndrome. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2019, 3, 684-694.	2.3	4
27	TCT-415 Platelet Reactivity Inhibition Following Ticagrelor Loading Dose in Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2019, 74, B411.	2.8	0
28	Common Risk Factors Add to Inherited Thrombophilia to Predict Venous Thromboembolism Risk in Families. <i>TH Open</i> , 2019, 03, e28-e35.	1.4	10
29	Augmenting pharmacotherapy with neuromodulation techniques for the treatment of bipolar disorder: a focus on the effects of mood stabilizers on cortical excitability. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1575-1588.	1.8	13
30	Thromboxane ϵ^2 prostaglandin receptor antagonist, terutroban, prevents neurovascular events after subarachnoid haemorrhage: a nanoSPECT study in rats. <i>Critical Care</i> , 2019, 23, 42.	5.8	10
31	Minor allele of the factor V K858R variant protects from venous thrombosis only in non-carriers of factor V Leiden mutation. <i>Scientific Reports</i> , 2019, 9, 3750.	3.3	7
32	Binding of Coagulation Factor XIII Zymogen to Activated Platelet Subpopulations: Roles of Integrin α IIb β 3 and Fibrinogen. <i>Thrombosis and Haemostasis</i> , 2019, 119, 906-915.	3.4	13
33	Lipodystrophy-like features after total body irradiation among survivors of childhood acute leukemia. <i>Endocrine Connections</i> , 2019, 8, 349-359.	1.9	2
34	Long-term management of leukocyte adhesion deficiency type III without hematopoietic stem cell transplantation. <i>Haematologica</i> , 2018, 103, e264-e267.	3.5	20
35	Anti α IIb β 3 immunization in Glanzmann thrombasthenia: review of literature and treatment recommendations. <i>British Journal of Haematology</i> , 2018, 181, 173-182.	2.5	17
36	A new heterozygous mutation in <i>GP1BA</i> gene responsible for macrothrombocytopenia. <i>British Journal of Haematology</i> , 2018, 183, 503-506.	2.5	8

#	ARTICLE	IF	CITATIONS
37	Interplay Among Psychopathologic Variables, Personal Resources, Context-Related Factors, and Real-life Functioning in Individuals With Schizophrenia. <i>JAMA Psychiatry</i> , 2018, 75, 396.	11.0	214
38	Mutations of the integrin α IIb β 3 intracytoplasmic salt bridge cause macrothrombocytopenia and enlarged platelet α -granules. <i>American Journal of Hematology</i> , 2018, 93, 195-204.	4.1	17
39	Assessment of platelet function on the routine coagulation analyzer Sysmex CS-2000i. <i>Platelets</i> , 2018, 29, 95-97.	2.3	17
40	Protease-activated receptor 1 inhibition protects mice against thrombin-dependent respiratory syncytial virus and human metapneumovirus infections. <i>British Journal of Pharmacology</i> , 2018, 175, 388-403.	5.4	14
41	The Annexin A1 Receptor FPR2 Regulates the Endosomal Export of Influenza Virus. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1400.	4.1	12
42	From Naproxen Repurposing to Naproxen Analogues and Their Antiviral Activity against Influenza A Virus. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 7202-7217.	6.4	32
43	Clinical and Laboratory Findings in Patients with β -Storage Pool Disease: A Case Series. <i>Seminars in Thrombosis and Hemostasis</i> , 2017, 43, 048-058.	2.7	26
44	Modulation of T Cell Activation in Obesity. <i>Antioxidants and Redox Signaling</i> , 2017, 26, 489-500.	5.4	17
45	Germline variants in <i>ETV6</i> underlie reduced platelet formation, platelet dysfunction and increased levels of circulating CD34 ⁺ progenitors. <i>Haematologica</i> , 2017, 102, 282-294.	3.5	70
46	Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 58, 3070-3078.	2.2	316
47	Antiviral activity of formyl peptide receptor 2 antagonists against influenza viruses. <i>Antiviral Research</i> , 2017, 143, 252-261.	4.1	16
48	Protein S Heerlen mutation heterozygosity is associated with venous thrombosis risk. <i>Scientific Reports</i> , 2017, 7, 45507.	3.3	14
49	Macrothrombocytopenia and dense granule deficiency associated with FLI1 variants: ultrastructural and pathogenic features. <i>Haematologica</i> , 2017, 102, 1006-1016.	3.5	34
50	Hematopoietic stem cell transplantation for the treatment of leukocyte adhesion deficiency type III. <i>Pediatrics and Neonatology</i> , 2017, 58, 560-561.	0.9	3
51	Phenotype analysis and clinical management in a large family with a novel truncating mutation in RASGRP2, the CalDAG-GEF1 encoding gene. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2017, 1, 128-133.	2.3	14
52	Expanded repertoire of RASGRP2 variants responsible for platelet dysfunction and severe bleeding. <i>Blood</i> , 2017, 130, 1026-1030.	1.4	38
53	Genetic risk factors for venous thrombosis in women using combined oral contraceptives: update of the <i>PILGRIM</i> study. <i>Clinical Genetics</i> , 2017, 91, 131-136.	2.0	7
54	Benefit of Switching Dual Antiplatelet Therapy After Acute Coronary Syndrome According to On-Treatment Platelet Reactivity. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 2560-2570.	2.9	36

#	ARTICLE	IF	CITATIONS
55	Peripartum bleeding management in a patient with Cal ^{DAG} deficiency. <i>Haemophilia</i> , 2017, 23, e533-e535.	2.1	5
56	Î-storage pool disease: an underestimated cause of unexplained bleeding. <i>Hematologie</i> , 2017, 23, 243-254.	0.0	4
57	FPR2: A Novel Promising Target for the Treatment of Influenza. <i>Frontiers in Microbiology</i> , 2017, 8, 1719.	3.5	27
58	Strengths and weaknesses of platelet aggregation in diagnosis of hereditary platelet disorders. <i>Hematologie</i> , 2017, 23, 298-311.	0.0	1
59	Alterations of the Platelet Procoagulant or Fibrinolytic Functions. , 2017, , 937-949.		0
60	Vascular risk levels affect the predictive value of platelet reactivity for the occurrence of MACE in patients on clopidogrel. <i>Thrombosis and Haemostasis</i> , 2016, 115, 823-825.	3.4	32
61	Risk factors for venous thromboembolism in women under combined oral contraceptive. <i>Thrombosis and Haemostasis</i> , 2016, 115, 135-142.	3.4	35
62	The first intracellular loop of GLUT4 contains a retention motif. <i>Journal of Cell Science</i> , 2016, 129, 2273-84.	2.0	2
63	398 Metabolic Effect in a New Experimental Model of Gastric Bypass Using Luminal Apposing Stent and Surgical Endoscopy. <i>Gastrointestinal Endoscopy</i> , 2016, 83, AB145.	1.0	0
64	Formyl Peptide Receptor 2 Plays a Deleterious Role During Influenza A Virus Infections. <i>Journal of Infectious Diseases</i> , 2016, 214, 237-247.	4.0	34
65	A high-throughput sequencing test for diagnosing inherited bleeding, thrombotic, and platelet disorders. <i>Blood</i> , 2016, 127, 2791-2803.	1.4	157
66	Changes in Activated Thrombin-Activatable Fibrinolysis Inhibitor Levels Following Thrombolytic Therapy in Ischemic Stroke Patients Correlate with Clinical Outcome. <i>Cerebrovascular Diseases</i> , 2016, 42, 404-414.	1.7	16
67	Î±1-antitrypsin Pittsburgh and plasmin-mediated proteolysis. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 2023-2026.	3.8	4
68	Early matrix metalloproteinase-9 concentration in the first 48h after aneurysmal subarachnoid haemorrhage predicts delayed cerebral ischaemia. <i>European Journal of Anaesthesiology</i> , 2016, 33, 662-669.	1.7	23
69	Is platelet inhibition correlated with time from last intake on P2Y12 blockers after an acute coronary syndrome? A pilot study. <i>Platelets</i> , 2016, 27, 791-795.	2.3	1
70	Haematological spectrum and genotype-phenotype correlations in nine unrelated families with RUNX1 mutations from the French network on inherited platelet disorders. <i>Orphanet Journal of Rare Diseases</i> , 2016, 11, 49.	2.7	86
71	Successful use of eltrombopag for surgical preparation in a patient with ANKRD26-related thrombocytopenia. <i>Platelets</i> , 2016, 27, 828-829.	2.3	13
72	Hysteresis-like binding of coagulation factors X/Xa to procoagulant activated platelets and phospholipids results from multistep association and membrane-dependent multimerization. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2016, 1858, 1216-1227.	2.6	21

#	ARTICLE	IF	CITATIONS
73	Immediate Postnatal Overfeeding in Rats Programs Aortic Wall Structure Alterations and Metalloproteinases Dysregulation in Adulthood. <i>American Journal of Hypertension</i> , 2016, 29, 719-726.	2.0	4
74	Phenotype Analysis and Clinical Management in a Large Family with a Novel Truncating Mutation in RASGRP2, the Caldag-GEFI Encoding Gene. <i>Blood</i> , 2016, 128, 3713-3713.	1.4	1
75	Gray platelet syndrome can mimic autoimmune lymphoproliferative syndrome. <i>Blood</i> , 2015, 126, 1967-1969.	1.4	21
76	Expanding the Mutation Spectrum Affecting α IIb β 3 Integrin in Glanzmann Thrombasthenia: Screening of the <i>ITGA2B</i> and <i>ITGB3</i> Genes in a Large International Cohort. <i>Human Mutation</i> , 2015, 36, 548-561.	2.5	67
77	Multilevel systems biology modeling characterized the atheroprotective efficiencies of modified dairy fats in a hamster model. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2015, 309, H935-H945.	3.2	12
78	Chronic kidney disease has a significant impact on platelet inhibition of new P2Y12 inhibitors. <i>International Journal of Cardiology</i> , 2015, 184, 428-430.	1.7	7
79	Ectopic fat storage in the pancreas using 1H-MRS: importance of diabetic status and modulation with bariatric surgery-induced weight loss. <i>International Journal of Obesity</i> , 2015, 39, 480-487.	3.4	84
80	CD28 deletion improves obesity-induced liver steatosis but increases adiposity in mice. <i>International Journal of Obesity</i> , 2015, 39, 977-985.	3.4	13
81	Genetic determined low response to thienopyridines is associated with higher systemic inflammation in smokers. <i>Pharmacogenomics</i> , 2015, 16, 459-469.	1.3	0
82	The Transcriptional Effects of PCB118 and PCB153 on the Liver, Adipose Tissue, Muscle and Colon of Mice: Highlighting of Glut4 and Lipin1 as Main Target Genes for PCB Induced Metabolic Disorders. <i>PLoS ONE</i> , 2015, 10, e0128847.	2.5	21
83	Pathophysiology of inherited platelet disorders. <i>Hematologie</i> , 2014, 20, 20-35.	0.0	3
84	Pathophysiology of inherited platelet disorders. <i>Sang Thrombose Vaisseaux</i> , 2014, 26, 300-316.	0.1	0
85	Efficacy of terutroban in preventing delayed cerebral ischemia after subarachnoid haemorrhage: a functional isotope imaging study on a rat model. <i>European Journal of Anaesthesiology</i> , 2014, 31, 109.	1.7	0
86	Systemic inhibition and liver-specific overexpression of PAI-1 failed to improve survival in all-inclusive populations or homogenous cohorts of CLP mice. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 958-969.	3.8	10
87	Risk assessment of venous thrombosis in families with known hereditary thrombophilia: the MARseilles-INImes prediction model. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 138-146.	3.8	17
88	Safety and effectiveness of the association ezetimibe-statin (E-S) versus high dose rosuvastatin after acute coronary syndrome: The SAFE-ES study. <i>Annales De Cardiologie Et D'Angéiologie</i> , 2014, 63, 222-227.	0.6	7
89	Fixed-dose aspirin-clopidogrel combination enhances compliance to aspirin after acute coronary syndrome. <i>International Journal of Cardiology</i> , 2014, 172, e1-e2.	1.7	13
90	Impact of Obesity and the Metabolic Syndrome on Response to Clopidogrel or Prasugrel and Bleeding Risk in Patients Treated After Coronary Stenting. <i>American Journal of Cardiology</i> , 2014, 113, 54-59.	1.6	35

#	ARTICLE	IF	CITATIONS
91	Spectrum of the Mutations in Bernard-Soulier Syndrome. <i>Human Mutation</i> , 2014, 35, 1033-1045.	2.5	124
92	Human CalDAG-GEFI gene (<i>RASGRP2</i>) mutation affects platelet function and causes severe bleeding. <i>Journal of Experimental Medicine</i> , 2014, 211, 1349-1362.	8.5	117
93	Effectiveness of switching "low responders"™ to prasugrel to ticagrelor after acute coronary syndrome. <i>International Journal of Cardiology</i> , 2014, 176, 1184-1185.	1.7	10
94	Body mass index has no impact on platelet inhibition induced by ticagrelor after acute coronary syndrome, conversely to prasugrel. <i>International Journal of Cardiology</i> , 2014, 176, 1200-1202.	1.7	21
95	Reply. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 108.	2.9	0
96	Impact of new P2Y12 blockers on platelet reactivity and clinical outcomes after acute coronary syndrome: Insight from a large single center registry. <i>International Journal of Cardiology Heart & Vessels</i> , 2014, 4, 188-192.	0.5	4
97	A meta-analysis of genome-wide association studies identifies ORM1 as a novel gene controlling thrombin generation potential. <i>Blood</i> , 2014, 123, 777-785.	1.4	27
98	First case of a human <i>RASGRP2</i> mutation affecting Rap1 activation in platelets and causing severe bleeding. <i>Journal of Cell Biology</i> , 2014, 206, 2061OIA111.	5.2	0
99	Clinical Implications of Very Low On-Treatment Platelet Reactivity in Patients Treated With Thienopyridine. <i>JACC: Cardiovascular Interventions</i> , 2013, 6, 854-863.	2.9	67
100	Prasugrel versus ticagrelor in acute coronary syndrome: A randomized comparison. <i>International Journal of Cardiology</i> , 2013, 170, e21-e22.	1.7	24
101	Predictors of long-term high on-treatment platelet reactivity in clopidogrel-treated patients undergoing coronary stenting for acute coronary syndrome. <i>International Journal of Cardiology</i> , 2013, 168, 1565-1566.	1.7	2
102	Platelet reactivity in diabetic patients undergoing coronary stenting for acute coronary syndrome treated with clopidogrel loading dose followed by prasugrel maintenance therapy. <i>International Journal of Cardiology</i> , 2013, 168, 523-528.	1.7	21
103	Effect of motivational mobile phone short message service on aspirin adherence after coronary stenting for acute coronary syndrome. <i>International Journal of Cardiology</i> , 2013, 168, 568-569.	1.7	65
104	Procoagulant Platelets Form an α -Granule Protein-covered "Cap" on Their Surface That Promotes Their Attachment to Aggregates. <i>Journal of Biological Chemistry</i> , 2013, 288, 29621-29632.	3.4	74
105	Effectiveness of switching "hyper responders"™ from Prasugrel to Clopidogrel after acute coronary syndrome: The POBA (Predictor of Bleeding with Antiplatelet drugs) SWITCH study. <i>International Journal of Cardiology</i> , 2013, 168, 5004-5005.	1.7	15
106	Off-label use of prasugrel in stable coronary artery disease is associated with greater degree of platelet inhibition compared with use after acute coronary syndrome. <i>International Journal of Cardiology</i> , 2013, 168, 2988-2989.	1.7	7
107	Palmitoylation of TNF alpha is involved in the regulation of TNF receptor 1 signalling. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2013, 1833, 602-612.	4.1	37
108	Prasugrel Monitoring and Bleeding in Real World Patients. <i>American Journal of Cardiology</i> , 2013, 111, 38-44.	1.6	41

#	ARTICLE	IF	CITATIONS
109	Effect of CYP2C19*2 and *17 Genetic Variants on Platelet Response to Clopidogrel and Prasugrel Maintenance Dose and Relation to Bleeding Complications. <i>American Journal of Cardiology</i> , 2013, 111, 985-990.	1.6	59
110	Effectiveness of switching hyper responders from prasugrel to clopidogrel after acute coronary syndrome: the POBA SWITCH study. <i>European Heart Journal</i> , 2013, 34, P4883-P4883.	2.2	0
111	Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridine: the POBA study (Predictor Of Bleedings with Antiplatelet drugs). <i>European Heart Journal</i> , 2013, 34, 4528-4528.	2.2	0
112	Microparticle increase in severe obesity: Not related to metabolic syndrome and unchanged after massive weight loss. <i>Obesity</i> , 2013, 21, 2236-2243.	3.0	114
113	ANKRD26-related thrombocytopenia and myeloid malignancies. <i>Blood</i> , 2013, 122, 1987-1989.	1.4	145
114	Impact of obesity on response to thienopyridine and bleeding risk in patients treated after acute coronary syndrome by clopidogrel or prasugrel. <i>European Heart Journal</i> , 2013, 34, P4878-P4878.	2.2	0
115	Obesity and vascular disease: From bench to bedside. <i>Thrombosis and Haemostasis</i> , 2013, 110, 632-633.	3.4	1
116	Thrombosis in central obesity and metabolic syndrome: Mechanisms and epidemiology. <i>Thrombosis and Haemostasis</i> , 2013, 110, 669-680.	3.4	121
117	Diet Modulates Endogenous Thrombin Generation, A Biological Estimate of Thrombosis Risk, Independently of the Metabolic Status. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2012, 32, 2394-2404.	2.4	26
118	Assessment of epicardial fat volume and myocardial triglyceride content in severely obese subjects: relationship to metabolic profile, cardiac function and visceral fat. <i>International Journal of Obesity</i> , 2012, 36, 422-430.	3.4	89
119	Dysmegakaryopoiesis of FPD/AML pedigrees with constitutional RUNX1 mutations is linked to myosin II deregulated expression. <i>Blood</i> , 2012, 120, 2708-2718.	1.4	93
120	Epicardial Fat Volume Is Associated With Coronary Microvascular Response in Healthy Subjects: A Pilot Study. <i>Obesity</i> , 2012, 20, 1200-1205.	3.0	24
121	ABO Blood Group and von Willebrand Factor Levels Partially Explained the Incomplete Penetrance of Congenital Thrombophilia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2012, 32, 2021-2028.	2.4	19
122	Factors associated with the failure of clopidogrel dose-adjustment according to platelet reactivity monitoring to optimize P2Y12-ADP receptor blockade. <i>Thrombosis Research</i> , 2012, 130, 70-74.	1.7	12
123	Two Types of Procoagulant Platelets Are Formed Upon Physiological Activation and Are Controlled by Integrin α IIb β 3. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2012, 32, 2475-2483.	2.4	46
124	An evaluation of the effects of <i>Lactobacillus ingluviei</i> on body weight, the intestinal microbiome and metabolism in mice. <i>Microbial Pathogenesis</i> , 2012, 52, 61-68.	2.9	59
125	Endocytosis and intracellular processing of platelet microparticles by brain endothelial cells. <i>Journal of Cellular and Molecular Medicine</i> , 2012, 16, 1731-1738.	3.6	76
126	Comparison between initial and chronic response to clopidogrel therapy after coronary stenting for acute coronary syndrome and influence on clinical outcomes. <i>American Heart Journal</i> , 2012, 164, 327-333.	2.7	8

#	ARTICLE	IF	CITATIONS
127	Effects of Bariatric Surgery on Cardiac Ectopic Fat. <i>Journal of the American College of Cardiology</i> , 2012, 60, 1381-1389.	2.8	175
128	CYP2C19*2 and *17 Alleles Have a Significant Impact on Platelet Response and Bleeding Risk in Patients Treated With Prasugrel After Acute Coronary Syndrome. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 1280-1287.	2.9	92
129	In Vivo Assessment of Murine Elastase-induced Abdominal Aortic Aneurysm with High Resolution Magnetic Resonance Imaging. <i>European Journal of Vascular and Endovascular Surgery</i> , 2012, 44, 475-481.	1.5	9
130	Recent advances in the pharmacogenetics of clopidogrel. <i>Human Genetics</i> , 2012, 131, 653-664.	3.8	26
131	Caution in Interpreting Results from Imputation Analysis When Linkage Disequilibrium Extends over a Large Distance: A Case Study on Venous Thrombosis. <i>PLoS ONE</i> , 2012, 7, e38538.	2.5	17
132	The Plasminogen Activation System Modulates Differently Adipogenesis and Myogenesis of Embryonic Stem Cells. <i>PLoS ONE</i> , 2012, 7, e49065.	2.5	12
133	Exome sequencing identifies NBEAL2 as the causative gene for gray platelet syndrome. <i>Nature Genetics</i> , 2011, 43, 735-737.	21.4	245
134	Paraoxonase-1 and clopidogrel efficacy. <i>Nature Medicine</i> , 2011, 17, 1039-1039.	30.7	27
135	Évaluation de l'exposition à des adipocytes humains sous-cutanés en culture aux acides linoléiques conjugués par une approche multi-omique. <i>Oleagineux Corps Gras Lipides</i> , 2011, 18, 365-371.	0.2	0
136	Association of vitronectin and plasminogen activator inhibitor-1 levels with the risk of metabolic syndrome and type 2 diabetes mellitus. <i>Thrombosis and Haemostasis</i> , 2011, 106, 416-422.	3.4	34
137	Platelets Alter Gene Expression Profile in Human Brain Endothelial Cells in an In Vitro Model of Cerebral Malaria. <i>PLoS ONE</i> , 2011, 6, e19651.	2.5	32
138	KNG1 Ile581Thr and susceptibility to venous thrombosis. <i>Blood</i> , 2011, 117, 3692-3694.	1.4	53
139	CD11b+ leukocyte microparticles are associated with high-risk angiographic lesions and recurrent cardiovascular events in acute coronary syndromes. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 1870-1873.	3.8	16
140	Usefulness of High Clopidogrel Maintenance Dose According to CYP2C19 Genotypes in Clopidogrel Low Responders Undergoing Coronary Stenting for Non ST Elevation Acute Coronary Syndrome. <i>American Journal of Cardiology</i> , 2011, 108, 760-765.	1.6	40
141	Comparison of Platelet Reactivity and Clopidogrel Response in Patients ≥75 Years Versus <75 Years Undergoing Percutaneous Coronary Intervention for Non-ST-Segment Elevation Acute Coronary Syndrome. <i>American Journal of Cardiology</i> , 2011, 108, 1411-1416.	1.6	18
142	High prevalence of laminopathies among patients with metabolic syndrome. <i>Human Molecular Genetics</i> , 2011, 20, 3779-3786.	2.9	58
143	High Residual Platelet Reactivity and Thrombotic Events. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 2561-2561.	7.4	1
144	Plasminogen activator inhibitor 1 is an intracellular inhibitor of furin proprotein convertase. <i>Journal of Cell Science</i> , 2011, 124, 1224-1230.	2.0	38

#	ARTICLE	IF	CITATIONS
145	A Novel Leukocyte Adhesion Deficiency III Variant: Kindlin-3 Deficiency Results in Integrin- and Nonintegrin-Related Defects in Different Steps of Leukocyte Adhesion. <i>Journal of Immunology</i> , 2011, 186, 5273-5283.	0.8	59
146	p38 Mitogen Activated Protein Kinase Controls Two Successive-Steps During the Early Mesodermal Commitment of Embryonic Stem Cells. <i>Stem Cells and Development</i> , 2011, 20, 1233-1246.	2.1	26
147	Circulating Matrix Metalloproteinases in Infective Endocarditis: A Possible Marker of the Embolic Risk. <i>PLoS ONE</i> , 2011, 6, e18830.	2.5	18
148	Genetics of Venous Thrombosis: Insights from a New Genome Wide Association Study. <i>PLoS ONE</i> , 2011, 6, e25581.	2.5	127
149	Anticoagulant and antithrombotic properties of platelet protease nexin-1. <i>Blood</i> , 2010, 115, 97-106.	1.4	66
150	C4BPB/C4BPA is a new susceptibility locus for venous thrombosis with unknown protein Sâ€independent mechanism: results from genome-wide association and gene expression analyses followed by case-control studies. <i>Blood</i> , 2010, 115, 4644-4650.	1.4	61
151	A Follow-Up Study of a Genome-wide Association Scan Identifies a Susceptibility Locus for Venous Thrombosis on Chromosome 6p24.1. <i>American Journal of Human Genetics</i> , 2010, 86, 592-595.	6.2	57
152	A Follow-Up Study of a Genome-wide Association Scan Identifies a Susceptibility Locus for Venous Thrombosis on Chromosome 6p24.1. <i>American Journal of Human Genetics</i> , 2010, 86, 655.	6.2	0
153	Polymorphisms of the lamina maturation pathway and their association with the metabolic syndrome: the DESIR prospective study. <i>Journal of Molecular Medicine</i> , 2010, 88, 193-201.	3.9	5
154	Prothrombin G20210A carriers the genetic mutation and a history of venous thrombosis contributes to thrombin generation independently of factor II plasma levels. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 942-949.	3.8	17
155	Plasminogen activator inhibitor type-1 is an independent marker of metabolic disorders in young adults born small for gestational age. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 2608-2613.	3.8	10
156	A multi-stage multi-ethnic design strategy provides strong evidence that the BAI3 locus is associated with early-onset venous thromboembolism. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 2671-2679.	3.8	42
157	Adrenergic receptor polymorphisms and platelet reactivity after treatment with dual antiplatelet therapy with aspirin and clopidogrel in acute coronary syndrome. <i>Thrombosis and Haemostasis</i> , 2010, 103, 774-779.	3.4	9
158	Down-regulation of Tissue Inhibitor of Metalloproteinase-3 (TIMP-3) Expression Is Necessary for Adipocyte Differentiation. <i>Journal of Biological Chemistry</i> , 2010, 285, 6508-6514.	3.4	38
159	Secretory Type II Phospholipase A2 Is Produced and Secreted by Epicardial Adipose Tissue and Overexpressed in Patients with Coronary Artery Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 963-967.	3.6	85
160	Clopidogrel response: Head-to-head comparison of different platelet assays to identify clopidogrel non responder patients after coronary stenting. <i>Archives of Cardiovascular Diseases</i> , 2010, 103, 39-45.	1.6	53
161	Post-PCI fatal bleeding in aspirin and clopidogrel hyper responder. <i>International Journal of Cardiology</i> , 2010, 138, 212-213.	1.7	13
162	Comparison of rosuvastatin and atorvastatin on clopidogrel response and lipidic and inflammatory parameters after coronary stenting for acute coronary syndrome: The prospective, randomized OSCAR study (optimal statin therapy with clopidogrel after coronary revascularisation). <i>Thrombosis Research</i> , 2010, 126, e397-e399.	1.7	3

#	ARTICLE	IF	CITATIONS
163	Lack of effect of chronic kidney disease on clopidogrel response with high loading and maintenance doses of clopidogrel after Acute Coronary Syndrome. <i>Thrombosis Research</i> , 2010, 126, e400-e402.	1.7	24
164	Glycemic control and clopidogrel response. <i>American Heart Journal</i> , 2010, 159, e35.	2.7	0
165	Common susceptibility alleles are unlikely to contribute as strongly as the FV and ABO loci to VTE risk: results from a GWAS approach. <i>Blood</i> , 2009, 113, 5298-5303.	1.4	283
166	Platelet microparticles: a new player in malaria parasite cytoadherence to human brain endothelium. <i>FASEB Journal</i> , 2009, 23, 3449-3458.	0.5	103
167	Predictive Values of Post-Treatment Adenosine Diphosphate-Induced Aggregation and Vasodilator-Stimulated Phosphoprotein Index for Stent Thrombosis After Acute Coronary Syndrome in Clopidogrel-Treated Patients. <i>American Journal of Cardiology</i> , 2009, 104, 1078-1082.	1.6	66
168	The inflammatory receptor CD40 is expressed on human adipocytes: contribution to crosstalk between lymphocytes and adipocytes. <i>Diabetologia</i> , 2009, 52, 1152-1163.	6.3	104
169	Potential Contribution of Adipose Tissue to Elevated Serum Cystatin C in Human Obesity. <i>Obesity</i> , 2009, 17, 2121-2126.	3.0	122
170	Activated thrombin activatable fibrinolysis inhibitor levels are associated with the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 49-57.	3.8	169
171	The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndrome. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 1409-1411.	3.8	114
172	Enhanced post-clopidogrel platelet reactivity in diabetic patients is independently related to plasma fibrinogen level but not to glycemic control. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 1939-1941.	3.8	23
173	Relationship between aspirin and clopidogrel responses in acute coronary syndrome and clinical predictors of non response. <i>Thrombosis Research</i> , 2009, 123, 597-603.	1.7	72
174	Aspirin noncompliance is the major cause of aspirin resistance in patients undergoing coronary stenting. <i>American Heart Journal</i> , 2009, 157, 889-893.	2.7	78
175	Comparison of Omeprazole and Pantoprazole Influence on a High 150-mg Clopidogrel Maintenance Dose. <i>Journal of the American College of Cardiology</i> , 2009, 54, 1149-1153.	2.8	212
176	Platelet-endothelial cell interactions in cerebral malaria: The end of a cordial understanding. <i>Thrombosis and Haemostasis</i> , 2009, 102, 1093-1102.	3.4	64
177	Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome.. <i>EuroIntervention</i> , 2009, 5, 325-329.	3.2	123
178	Glycoprotein IIb/IIIa Inhibitors Improve Outcome After Coronary Stenting in Clopidogrel Nonresponders. <i>JACC: Cardiovascular Interventions</i> , 2008, 1, 649-653.	2.9	140
179	Characterization of human mesenchymal stem cell secretome at early steps of adipocyte and osteoblast differentiation. <i>BMC Molecular Biology</i> , 2008, 9, 26.	3.0	117
180	Progression of atherosclerosis in ApoE-deficient mice that express distinct molecular forms of TNF- α . <i>Journal of Pathology</i> , 2008, 214, 574-583.	4.5	41

#	ARTICLE	IF	CITATIONS
181	HDLs activate ADAM17-dependent shedding. <i>Journal of Cellular Physiology</i> , 2008, 214, 687-693.	4.1	38
182	Epicardial Adipose Tissue Extent: Relationship With Age, Body Fat Distribution, and Coronaropathy. <i>Obesity</i> , 2008, 16, 2424-2430.	3.0	134
183	Pharmacokinetics and pharmacodynamics of a new highly secured fibrinogen concentrate. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 1494-1499.	3.8	39
184	Relation between the antithrombin Cambridge II mutation, the risk of venous thrombosis, and the endogenous thrombin generation. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 1975-1977.	3.8	13
185	Effect of Cytochrome P450 Polymorphisms on Platelet Reactivity After Treatment With Clopidogrel in Acute Coronary Syndrome. <i>American Journal of Cardiology</i> , 2008, 101, 1088-1093.	1.6	194
186	Adjusting Clopidogrel Loading Doses According to Vasodilator-Stimulated Phosphoprotein Index: On Time, Too Early, or Too Late?. <i>Journal of the American College of Cardiology</i> , 2008, 52, 790-791.	2.8	2
187	Metabolic syndrome, haemostasis and thrombosis. <i>Thrombosis and Haemostasis</i> , 2008, 99, 995-1000.	3.4	163
188	Tissu adipeux viscéral et thrombose. <i>Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique</i> , 2008, 2008, 19-27.	0.0	0
189	Energy intake is associated with endotoxemia in apparently healthy men. <i>American Journal of Clinical Nutrition</i> , 2008, 87, 1219-1223.	4.7	498
190	Effect of sleep apnea syndrome on the circadian profile of cortisol in obese men. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2007, 293, E466-E474.	3.5	42
191	Association of Plasminogen Activator Inhibitor (PAI)-1 (SERPINE1) SNPs With Myocardial Infarction, Plasma PAI-1, and Metabolic Parameters. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007, 27, 2250-2257.	2.4	65
192	Plasminogen activator inhibitor-1, adipose tissue and insulin resistance. <i>Current Opinion in Lipidology</i> , 2007, 18, 240-245.	2.7	174
193	Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST-segment elevation acute coronary syndrome. <i>Thrombosis Research</i> , 2007, 120, 893-899.	1.7	77
194	Metabolic Endotoxemia Initiates Obesity and Insulin Resistance. <i>Diabetes</i> , 2007, 56, 1761-1772.	0.6	4,964
195	Does the anti-prothrombin antibodies measurement provide additional information in patients with thrombosis?. <i>Immunobiology</i> , 2007, 212, 557-565.	1.9	32
196	MRI follow-up of TNF-dependent differential progression of atherosclerotic wall-thickening in mouse aortic arch from early to advanced stages. <i>Atherosclerosis</i> , 2007, 195, e93-e99.	0.8	17
197	Microparticles of Human Atherosclerotic Plaques Enhance the Shedding of the Tumor Necrosis Factor- α Converting Enzyme/ADAM17 Substrates, Tumor Necrosis Factor and Tumor Necrosis Factor Receptor-1. <i>American Journal of Pathology</i> , 2007, 171, 1713-1723.	3.8	105
198	High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes. <i>Thrombosis and Haemostasis</i> , 2007, 97, 282-287.	3.4	102

#	ARTICLE	IF	CITATIONS
199	Antiphosphatidylethanolamine antibodies are associated with an increased odds ratio for thrombosis. <i>Thrombosis and Haemostasis</i> , 2007, 97, 949-954.	3.4	92
200	Lack of association between the 807 C/T polymorphism of glycoprotein Ia gene and post-treatment platelet reactivity after aspirin and clopidogrel in patients with acute coronary syndrome. <i>Thrombosis and Haemostasis</i> , 2007, 97, 212-217.	3.4	67
201	ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome. <i>Thrombosis and Haemostasis</i> , 2007, 98, 838-843.	3.4	203
202	Prognostic value of plasma tissue factor and tissue factor pathway inhibitor for cardiovascular death in patients with coronary artery disease: the AtheroGene study. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 475-482.	3.8	68
203	Chronic plasminogen activator inhibitor-1 (PAI-1) overexpression dampens CD25+ lymphocyte recruitment after lipopolysaccharide endotoxemia in mouse lung. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 2467-2475.	3.8	14
204	Meta-Analysis Appraising High Clopidogrel Loading in Patients Undergoing Percutaneous Coronary Intervention—Conflicts of interest: Dr. Angiolillo is a consultant and on the speaker's bureau for Bristol Myers Squibb, New York, New York, and Sanofi-Aventis, Paris, France. Dr. Biondi-Zoccai has consulted for Boston Scientific, Natick, Massachusetts, and Cordis, Miami, Florida, and received lecture fees from Bristol Myers Squibb. Dr. Montalescot has been a consultant for and/or received research grants from Sa. <i>American Journal of Cardiology</i> , 2007, 100, 1199-1206.	1.6	110
205	C3H/HeJ mice carrying a toll-like receptor 4 mutation are protected against the development of insulin resistance in white adipose tissue in response to a high-fat diet. <i>Diabetologia</i> , 2007, 50, 1267-1276.	6.3	309
206	Polymorphism A36G of the tumor necrosis factor receptor 1 gene is associated with PAI-1 levels in obese women. <i>Thrombosis and Haemostasis</i> , 2007, 97, 62-66.	3.4	10
207	Lack of association between the 807 C/T polymorphism of glycoprotein Ia gene and post-treatment platelet reactivity after aspirin and clopidogrel in patients with acute coronary syndrome. <i>Thrombosis and Haemostasis</i> , 2007, 97, 212-7.	3.4	5
208	ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome. <i>Thrombosis and Haemostasis</i> , 2007, 98, 838-43.	3.4	26
209	Tu-W19:2 Role of the fibrinolytic system in the development of obesity and the metabolic syndrome. <i>Atherosclerosis Supplements</i> , 2006, 7, 158.	1.2	0
210	The TNF alpha converting enzyme (TACE/ADAM17) is expressed in the atherosclerotic lesions of apolipoprotein E-deficient mice: Possible contribution to elevated plasma levels of soluble TNF alpha receptors. <i>Atherosclerosis</i> , 2006, 187, 82-91.	0.8	82
211	Benefit of a 600-mg Loading Dose of Clopidogrel on Platelet Reactivity and Clinical Outcomes in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome Undergoing Coronary Stenting. <i>Journal of the American College of Cardiology</i> , 2006, 48, 1339-1345.	2.8	329
212	Lipides peroxydés et réaction immuno-inflammatoire dans l'athérosclérose. <i>Oleagineux Corps Gras Lipides</i> , 2006, 13, 337-342.	0.2	0
213	Fine mapping of quantitative trait nucleotides underlying thrombin-activatable fibrinolysis inhibitor antigen levels by a transethnic study. <i>Blood</i> , 2006, 108, 1562-1568.	1.4	37
214	High post-treatment platelet reactivity identified low responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 542-549.	3.8	349
215	Insulin resistance induced by hydrocortisone is increased in patients with abdominal obesity. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2006, 291, E995-E1002.	3.5	52
216	Modulation of Adipose Tissue Development by Pharmacological Inhibition of PAI-1. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006, 26, 2209-2215.	2.4	82

#	ARTICLE	IF	CITATIONS
217	Expression of adrenomedullin in adipose tissue of lean and obese women. <i>European Journal of Endocrinology</i> , 2006, 155, 177-185.	3.7	27
218	PAI-1 and the Metabolic Syndrome. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006, 26, 2200-2207.	2.4	326
219	Tiplaxtinin impairs nutritionally induced obesity in mice. <i>Thrombosis and Haemostasis</i> , 2006, 96, 731-737.	3.4	19
220	TAFI levels in patients with acute myocardial infarction treated with thrombolysis. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 395-397.	3.8	4
221	On the role of plasminogen activator inhibitor-1 in adipose tissue development and insulin resistance in mice. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 1174-1179.	3.8	62
222	Biological and genetic factors influencing plasma factor VIII levels in a healthy family population: results from the Stanislas cohort. <i>British Journal of Haematology</i> , 2005, 128, 91-99.	2.5	80
223	Heterogeneity of anti- β_2 -glycoprotein I antibodies. <i>Thrombosis and Haemostasis</i> , 2005, 93, 80-87.	3.4	14
224	Quantification of thrombin activatable fibrinolysis inhibitor (TAFI) gene polymorphism effects on plasma levels of TAFI measured with assays insensitive to isoform-dependent artefact. <i>Thrombosis and Haemostasis</i> , 2005, 94, 373-9.	3.4	34
225	Interaction between the C-260T polymorphism of the CD14 gene and the plasma IL-6 concentration on the risk of myocardial infarction: the HIFMECH study. <i>Atherosclerosis</i> , 2005, 179, 317-323.	0.8	25
226	PCV18 WHEN SHOULD PATIENTS BE SWITCHED FROM VKATO NEW TREATMENT: DEVELOPMENT AND PILOT TESTING OF A SELF-REPORTED QUESTIONNAIRE TO TARGET PATIENTS WHO WOULD BENEFIT MOST. <i>Value in Health</i> , 2005, 8, A94.	0.3	0
227	PPAR α deficiency does not modify age dependency but prevents high fat diet increase in plasma PAI-1 as well as insulin resistance. <i>Thrombosis and Haemostasis</i> , 2004, 91, 1051-1052.	3.4	4
228	Endothelial Cell Markers and the Risk of Coronary Heart Disease. <i>Circulation</i> , 2004, 109, 1343-1348.	1.6	203
229	β -thalassaemia-87 C \rightarrow G: relationship of the Hb F modulation and polymorphisms in compound heterozygous patients. <i>British Journal of Haematology</i> , 2004, 126, 743-749.	2.5	6
230	A 13 base pair deletion in the GPIIb/3 gene in a second unrelated Bernard-Soulier family due to slipped mispairing between direct repeats. <i>Journal of Thrombosis and Haemostasis</i> , 2004, 2, 1663-1665.	3.8	6
231	Hypofibrinolysis in the insulin resistance syndrome: implication in cardiovascular diseases. <i>Journal of Internal Medicine</i> , 2004, 255, 448-456.	6.0	57
232	Relations between hemostatic variables, insulin resistance and inflammation. <i>The Hematology Journal</i> , 2004, 5, S15-S19.	1.4	2
233	Weak and non-independent association between plasma TAFI antigen levels and the insulin resistance syndrome. <i>Journal of Thrombosis and Haemostasis</i> , 2003, 1, 791-797.	3.8	55
234	Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. <i>Journal of Thrombosis and Haemostasis</i> , 2003, 1, 1575-1579.	3.8	315

#	ARTICLE	IF	CITATIONS
235	The plasminogen activator inhibitor-1 -675 4G/5G genotype influences the risk of myocardial infarction associated with elevated plasma proinsulin and insulin concentrations in men from Europe: the HIFMECH Study. <i>Journal of Thrombosis and Haemostasis</i> , 2003, 1, 2322-2329.	3.8	52
236	Expression of the mRNAs Coding for the Glucocorticoid Receptor Isoforms in Obesity. <i>Obesity</i> , 2003, 11, 925-929.	4.0	38
237	A Novel Missense Mutation Shows that GPIb ^{β2} Has a Dual Role in Controlling the Processing and Stability of the Platelet GPIb-IX Adhesion Receptor. <i>Biochemistry</i> , 2003, 42, 4452-4462.	2.5	27
238	Nutritionally Induced Obesity Is Attenuated in Transgenic Mice Overexpressing Plasminogen Activator Inhibitor-1. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2003, 23, 78-84.	2.4	91
239	Development of a Genotype 325 ^Δ -Specific proCPU/TAFI ELISA. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2003, 23, 1122-1127.	2.4	79
240	Plasma PAI-1 Levels Are More Strongly Related to Liver Steatosis Than to Adipose Tissue Accumulation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2003, 23, 1262-1268.	2.4	168
241	Adipose Tissue and Atherothrombosis. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2003, 33, 290-297.	0.3	54
242	Stromal Cells Are the Main Plasminogen Activator Inhibitor-1-Producing Cells in Human Fat. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2002, 22, 173-178.	2.4	182
243	Expression of the mRNA Coding for 11 ^β -Hydroxysteroid Dehydrogenase Type 1 in Adipose Tissue from Obese Patients: An <i>in Situ</i> Hybridization Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 2701-2705.	3.6	220
244	The insulin resistance syndrome: implications for thrombosis and cardiovascular disease. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2002, 32, 269-273.	0.3	60
245	Plasma Thrombin-Activatable Fibrinolysis Inhibitor Antigen Concentration and Genotype in Relation to Myocardial Infarction in the North and South of Europe. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2002, 22, 867-873.	2.4	137
246	Les statines en th ^é rapeutique cardiovasculaire. <i>Medecine/Sciences</i> , 2002, 18, 1257-1265.	0.2	0
247	Relationships between Fibrinolytic and Inflammatory Parameters in Human Adipose Tissue: Strong Contribution of TNF ^α Receptors to PAI-1 Levels. <i>Thrombosis and Haemostasis</i> , 2002, 88, 481-487.	3.4	32
248	Anti-phospholipid/cofactor antibodies in three cases of persistent polyclonal b lymphocytosis. <i>British Journal of Haematology</i> , 2002, 119, 875-876.	2.5	2
249	Expression of the mRNA Coding for 11 ^β -Hydroxysteroid Dehydrogenase Type 1 in Adipose Tissue from Obese Patients: An <i>in Situ</i> Hybridization Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 2701-2705.	3.6	186
250	Antibodies to Phosphatidylethanolamine as the only Antiphospholipid Antibodies Found in Patients with Unexplained Thromboses. <i>Thrombosis and Haemostasis</i> , 2001, 85, 800-805.	3.4	70
251	Adipose Tissue Expression of Gelatinases in Mouse Models of Obesity. <i>Thrombosis and Haemostasis</i> , 2001, 85, 1111-1116.	3.4	61
252	Identification of polymorphisms in the promoter and the 3 [′] region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled. <i>Blood</i> , 2001, 97, 2053-2058.	1.4	140

#	ARTICLE	IF	CITATIONS
253	Subcutaneous abdominal, but not femoral fat expression of plasminogen activator inhibitor-1 (PAI-1) is related to plasma PAI-1 levels and insulin resistance and decreases after weight loss. <i>Diabetologia</i> , 2001, 44, 2025-2031.	6.3	122
254	Système fibrinolytique, métalloproteases et pathologie vasculaire.. <i>Medecine/Sciences</i> , 2001, 17, 170.	0.2	5
255	Plasma TAFI Antigen Variations in Healthy Subjects. <i>Thrombosis and Haemostasis</i> , 2000, 83, 902-905.	3.4	99
256	Formation, Inhibition and Clearance of Plasmin in vivo. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2000, 30, 204-218.	0.3	19
257	The A ^{844G} Polymorphism in the PAI-1 Gene Is Associated With a Higher Risk of Venous Thrombosis in Factor V Leiden Carriers. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2000, 20, 1387-1391.	2.4	55
258	Fat Cell Function and Fibrinolysis. <i>Hormone and Metabolic Research</i> , 2000, 32, 504-508.	1.5	45
259	Plasminogen activator inhibitor 1, transforming growth factor-beta1, and BMI are closely associated in human adipose tissue during morbid obesity. <i>Diabetes</i> , 2000, 49, 1374-1380.	0.6	322
260	Thrombin-Activatable Fibrinolysis Inhibitor Antigen Levels and Cardiovascular Risk Factors. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2000, 20, 2156-2161.	2.4	86
261	Influence of PAI-1 on Adipose Tissue Growth and Metabolic Parameters in a Murine Model of Diet-Induced Obesity. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2000, 20, 1150-1154.	2.4	124
262	Rapid Detection of Factor XIII Val34Leu by Allele Specific PCR. <i>Thrombosis and Haemostasis</i> , 1999, 81, 463-463.	3.4	13
263	PAI-1 Produced Ex Vivo by Human Adipose Tissue Is Relevant to PAI-1 Blood Level. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1999, 19, 1361-1365.	2.4	99
264	Fibrinolytic function and coronary risk. <i>Current Cardiology Reports</i> , 1999, 1, 119-124.	2.9	28
265	<i>Chlamydia pneumoniae</i> DNA Detection in Peripheral Blood Mononuclear Cells Is Predictive of Vascular Infection. <i>Journal of Infectious Diseases</i> , 1999, 180, 2074-2076.	4.0	108
266	Glucocorticoids and insulin promote plasminogen activator inhibitor 1 production by human adipose tissue.. <i>Diabetes</i> , 1999, 48, 890-895.	0.6	117
267	Regulation of PAI-1 in obesity and insulin resistance. <i>Atherosclerosis</i> , 1999, 144, 14.	0.8	0
268	PAI-1, Obesity, and Insulin Resistance. , 1999, , 317-332.		5
269	Relationship of Plasminogen Activator Inhibitor-1 Levels following Thrombolytic Therapy with rt-PA as Compared to Streptokinase and Patency of Infarct Related Coronary Artery. <i>Thrombosis and Haemostasis</i> , 1999, 82, 104-108.	3.4	22
270	Regulation of Fibrinolysis in the Development of Atherothrombosis: Role of Adipose Tissue. <i>Thrombosis and Haemostasis</i> , 1999, 82, 832-836.	3.4	46

#	ARTICLE	IF	CITATIONS
271	Visceral fat as a main determinant of plasminogen activator inhibitor 1 level in women. <i>International Journal of Obesity</i> , 1998, 22, 312-317.	3.4	92
272	Metabolic Determinants Are Much More Important Than Genetic Polymorphisms in Determining the PAI-1 Activity and Antigen Plasma Concentrations. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1998, 18, 84-91.	2.4	123
273	A Three-generation Family Presenting Five Cases of Homozygosity for the 20210 G to A Prothrombin Variant. <i>Thrombosis and Haemostasis</i> , 1998, 80, 859-860.	3.4	14
274	PAI-1 and the Risk of Cardiovascular Disease. <i>Medical Science Symposia Series</i> , 1998, , 85-92.	0.0	4
275	2.W14.3 Impaired fibrinolysis and the risk of CHD. <i>Atherosclerosis</i> , 1997, 134, 111.	0.8	0
276	Variables of the fibrinolytic system: risk indicators for CHD. <i>Fibrinolysis and Proteolysis</i> , 1997, 11, 47-49.	1.1	1
277	PAI-1, Obesity, Insulin Resistance and Risk of Cardiovascular Events. <i>Thrombosis and Haemostasis</i> , 1997, 78, 656-660.	3.4	330
278	Acquired Protein S Deficiency, Likely due to Anti-PS Autoantibodies, following a Thrombotic Event in a Patient with a Systemic Lupus erythematosus. <i>Thrombosis and Haemostasis</i> , 1997, 78, 1416-1417.	3.4	12
279	Five Frequent Polymorphisms of the PAI-1 Gene. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1997, 17, 851-858.	2.4	81
280	Intracellular Calcium Mobilization Suppresses the TNF- α -Stimulated Synthesis of PAI-1 in Human Endothelial Cells. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1997, 17, 1550-1560.	2.4	25
281	Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. <i>Diabetes</i> , 1997, 46, 860-867.	0.6	175
282	Increase in cytosolic calcium upregulates the synthesis of type 1 plasminogen activator inhibitor in the human histiocytic cell line U937. <i>Blood</i> , 1996, 87, 162-173.	1.4	25
283	Presence of autoantibodies to interleukin-8 or neutrophil-activating peptide-2 in patients with heparin-associated thrombocytopenia. <i>Blood</i> , 1996, 88, 410-416.	1.4	240
284	Iloprost and salvage of a free flap. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 1996, 49, 245-248.	1.1	22
285	Fibrinolysis and risk of coronary artery disease. <i>Fibrinolysis</i> , 1996, 10, 127-136.	0.5	35
286	Thrombogenic and Fibrinolytic Factors and Cardiovascular Risk in Non-insulin-dependent Diabetes Mellitus. <i>Annals of Medicine</i> , 1996, 28, 371-380.	3.8	138
287	New Direct Assay of Free Protein S Antigen Applied to Diagnosis of Protein S Deficiency. <i>Thrombosis and Haemostasis</i> , 1996, 75, 283-285.	3.4	23
288	Purpura Fulminans in a Patient Homozygous for a Mutation in the Protein C Gene - Prenatal Diagnosis in a Subsequent Pregnancy. <i>Thrombosis and Haemostasis</i> , 1996, 75, 525-526.	3.4	6

#	ARTICLE	IF	CITATIONS
289	Fibrinolytic Factors and the Risk of Myocardial Infarction or Sudden Death in Patients With Angina Pectoris. <i>Circulation</i> , 1996, 94, 2057-2063.	1.6	437
290	Fibrinolytic and inflammatory processes in pleural effusions. <i>European Respiratory Journal</i> , 1995, 8, 1352-1356.	6.7	105
291	Up-regulation of PAI-1 synthesis by insulin and proinsulin in HEP G2 cells but not in endothelial cells. <i>Fibrinolysis</i> , 1995, 9, 237-242.	0.5	23
292	4 Pathophysiology of fibrinolysis. <i>Best Practice and Research: Clinical Haematology</i> , 1995, 8, 329-343.	1.1	19
293	Plasma Plasminogen Activator Inhibitor Activity in Rats with Nutritionally Induced Insulin Resistance. <i>Thrombosis and Haemostasis</i> , 1995, 74, 806-807.	3.4	3
294	Relation between Plasma PAI Activity and Adipsin Levels. <i>Thrombosis and Haemostasis</i> , 1995, 74, 1200-1202.	3.4	13
295	Up-Regulated Expression of Plasminogen Activator Inhibitor-1 in Hep G2 Cells: Interrelationship between Insulin and Insulin-Like Growth Factor 1. <i>Thrombosis and Haemostasis</i> , 1995, 73, 268-274.	3.4	20
296	Intraperitoneal Insulin Administration Does Not Modify Plasminogen Activator Inhibitor 1 Levels in IDDM Patients. <i>Diabetes Care</i> , 1994, 17, 941-942.	8.6	5
297	Cutaneous Necrosis Associated with Acquired Severe Protein S Deficiency. <i>Thrombosis and Haemostasis</i> , 1994, 71, 396-396.	3.4	4
298	Plasminogen Activator Inhibitor-1 Expression in Human Liver and Healthy or Atherosclerotic Vessel Walls. <i>Thrombosis and Haemostasis</i> , 1994, 72, 044-053.	3.4	99
299	Detection of Plasminogen Activator Inhibitor-1 (PAI-1) mRNA in Human Megakaryocytes by In Situ Hybridization. <i>Thrombosis and Haemostasis</i> , 1994, 72, 931-936.	3.4	26
300	Plasminogen activator inhibitor activity in various types of endogenous hypertriglyceridemia. <i>Fibrinolysis</i> , 1993, 7, 171-176.	0.5	25
301	Granulocyte-endothelium initial adhesion. Analysis of transient binding events mediated by E-selectin in a laminar shear flow. <i>Biophysical Journal</i> , 1993, 64, 1922-1933.	0.5	180
302	Plasminogen Activator Inhibitor 1 and Atherothrombosis. <i>Thrombosis and Haemostasis</i> , 1993, 70, 138-143.	3.4	171
303	Plasminogen activator inhibitor-1 synthesis in the human hepatoma cell line Hep G2. Metformin inhibits the stimulating effect of insulin. <i>Journal of Clinical Investigation</i> , 1993, 91, 2185-2193.	8.2	67
304	Fibrinolysis in insulin dependent diabetic patients with or without nephropathy. <i>Fibrinolysis</i> , 1992, 6, 105-109.	0.5	24
305	Daytime Fluctuations of Plasminogen Activator Inhibitor 1 (PAI-1) in Populations with High PAI-1 Levels. <i>Thrombosis and Haemostasis</i> , 1992, 67, 076-082.	3.4	33
306	Lupus anticoagulant in silica-induced scleroderma. <i>Clinical Rheumatology</i> , 1992, 11, 444-445.	2.2	0

#	ARTICLE	IF	CITATIONS
307	Venous Occlusion Does Not Induce the Release of Thrombomodulin from Endothelial Cells in Patients with Thromboembolic Disease. <i>Thrombosis and Haemostasis</i> , 1992, 68, 483-484.	3.4	5
308	Molecular forms of plasminogen activator inhibitor-1 (PAI-1) and tissue-type plasminogen activator (t-PA) in human plasma. <i>Thrombosis Research</i> , 1991, 62, 275-285.	1.7	18
309	Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis. <i>Diabetologia</i> , 1991, 34, 457-462.	6.3	549
310	Stimulating effect of oxidized low density lipoproteins on plasminogen activator inhibitor-1 synthesis by endothelial cells.. <i>Arteriosclerosis and Thrombosis: A Journal of Vascular Biology</i> , 1991, 11, 1821-1829.	3.9	98
311	Characterization of Epitheloid Cells from Human Omentum: Comparison with Endothelial Cells from Umbilical Veins. <i>Thrombosis and Haemostasis</i> , 1991, 66, 361-367.	3.4	22
312	Effect of low density lipoproteins on secretion of plasminogen activator inhibitor-1 (PAI-1) by human endothelial cells and hepatoma cells. <i>Fibrinolysis</i> , 1990, 4, 82-83.	0.5	18
313	The determination of functional plasminogen activator inhibitors (PAI) based on the inhibition of urokinase: PAI normal range and circadian variations in healthy donors; Comparison with other methods. <i>Fibrinolysis</i> , 1990, 4, 177-181.	0.5	6
314	Correlations between t-PA and PAI-1 antigen and activity and t-PA/PAI-1 complexes in plasma of control subjects and of patients with increased t-PA or PAI-1 levels. <i>Thrombosis Research</i> , 1990, 60, 509-516.	1.7	49
315	Lupus anticoagulants and antiphospholipid antibodies: Comparison of clotting tests with an immunological assay. <i>Thrombosis Research</i> , 1990, 60, 181-183.	1.7	1
316	The increased plasma Lp(a) : B lipoprotein particle concentration in angina pectoris is not associated with hypofibrinolysis. <i>Clinica Chimica Acta</i> , 1990, 188, 119-127.	1.1	33
317	Secretion of tissue-type plasminogen activator and plasminogen activator inhibitor by <i>Rickettsia conorii</i> - and <i>Rickettsia rickettsii</i> -infected cultured endothelial cells. <i>Infection and Immunity</i> , 1990, 58, 2459-2463.	2.2	33
318	Plasma plasminogen activator inhibitor-1 in angina pectoris. Influence of plasma insulin and acute-phase response.. <i>Arteriosclerosis (Dallas, Tex)</i> , 1989, 9, 362-367.	4.9	205
319	Potentialiation by Heparin Fragment CY 222 (CHOAY) of Thrombolysis Induced by Human Tissue-Type Plasminogen Activator. <i>Seminars in Thrombosis and Hemostasis</i> , 1989, 15, 390-394.	2.7	2
320	Fat distribution and plasminogen activator inhibitor activity in nondiabetic obese women. <i>Metabolism: Clinical and Experimental</i> , 1989, 38, 913-915.	3.4	135
321	Purification and characterization of natural and recombinant human plasminogen activator inhibitor-1 (PAI-1). <i>FEBS Journal</i> , 1988, 175, 531-540.	0.2	75
322	Relevance of Free tPA Assay Following Venous Occlusion in Patients with Venous Thromboembolic Disease. <i>Thrombosis and Haemostasis</i> , 1988, 59, 346-347.	3.4	8
323	RELEVANCE OF FREE t-PA ASSAY FOLLOWING VENOUS OCCLUSION IN PATIENTS WITH VENOUS THROMBOEMBOLIC DISEASE. , 1987, 58, 1627.		0
324	EFFECT OF DIFFERENT HEPARINS ON THROMBOLYSIS WITH t-PA AND scu-PA IN RABBITS WITH EXPERIMENTAL THROMBOSIS. , 1987, 58, 0993.		0

#	ARTICLE	IF	CITATIONS
325	Potential by Heparin Fragments of Thrombolysis Induced with Human Tissue-Type Plasminogen Activator or Human Single-Chain Urokinase-Type Plasminogen Activator. <i>Thrombosis and Haemostasis</i> , 1987, 58, 947-950.	3.4	46
326	Deficient t-PA Release and Elevated PA Inhibitor Levels in Patients with Spontaneous or Recurrent Deep Venous Thrombosis. <i>Thrombosis and Haemostasis</i> , 1987, 57, 067-072.	3.4	343
327	Metformin Decreases the High Plasminogen Activator Inhibition Capacity, Plasma Insulin and Triglyceride Levels in Non-Diabetic Obese Subjects. <i>Thrombosis and Haemostasis</i> , 1987, 57, 326-328.	3.4	152
328	Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects. <i>Metabolism: Clinical and Experimental</i> , 1986, 35, 250-253.	3.4	442
329	Screening platelet function in blood donors. <i>Transfusion</i> , 0, , .	1.6	2